camptothecin/podophyllotoxin (NEV-801) / Neovia Oncology 
Welcome,         Profile    Billing    Logout  

1 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
camptothecin/podophyllotoxin (NEV-801) / Neovia Oncology
NCT02797795: A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers

Recruiting
1
78
US
NEV801
Neovia Oncology Ltd.
Advanced Cancer, Solid Tumors
12/21
12/21

Download Options